Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President

Chief Executive Officer

Chief Medical Officer

Chief Financial Officer

President and CSO

Chief Innovation Officer

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization o...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-01	Premium	acquired	Premium	Premium	Premium	President
2024-01-01	Premium	acquired	Premium	Premium	Premium	-
2023-12-01	Premium	acquired	Premium	Premium	Premium	-
2023-11-30	Premium	acquired	Premium	Premium	Premium	-
2023-11-30	Premium	acquired	Premium	Premium	Premium	-
2023-11-30	Premium	acquired	Premium	Premium	Premium	-
2023-11-30	Premium	acquired	Premium	Premium	Premium	-
2023-08-09	Premium	sold	Premium	Premium	Premium	-
2023-05-19	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-06-03	Premium	bought	Premium	Premium	Premium	-
2021-06-03	Premium	bought	Premium	Premium	Premium	-
2021-06-03	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-06-03	Premium	bought	Premium	Premium	Premium	-
2021-05-06	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-05-05	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-05-04	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-02-25	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2021-02-25	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2020-12-28	Premium	sold	Premium	Premium	Premium	President and CSO
2020-11-09	Premium	bought	Premium	Premium	Premium	Chief Innovation Officer
2020-11-06	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2020-02-21	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2019-12-30	Premium	sold	Premium	Premium	Premium	President
2019-12-27	Premium	sold	Premium	Premium	Premium	President
2019-11-15	Premium	bought	Premium	Premium	Premium	Chief Innovation Officer

CYCN - Cyclerion Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CYCN